* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co ROE % Adjusted to Book Value Chart
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Annual Data
FRA:FDY vs ZTS, UTHR: ROE % Adjusted to Book Value Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co ROE % Adjusted to Book Value vs Drug Manufacturers Industry
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROE % Adjusted to Book Value of -20.68% mean?
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co (FRA:FDY) has a ROE % Adjusted to Book Value of -20.68% as of Dec. 2025. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co and its competitors.
Is Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's ROE % Adjusted to Book Value too high?
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's current ROE % Adjusted to Book Value is -20.68%. Overall, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co has a GF Score™ of 72/100, reflecting its overall financial health beyond just this single metric.
How does Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's ROE % Adjusted to Book Value compare to ZTS and UTHR?
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's ROE % Adjusted to Book Value of -20.68% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Drug Manufacturers company?
A good ROE % Adjusted to Book Value depends on the Drug Manufacturers industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co and its competitors. Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's current ROE % Adjusted to Book Value is -20.68%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co stock overvalued right now?
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co (FRA:FDY) has a current ROE % Adjusted to Book Value of -20.68%. The stock's GF Value™ is €0.24, compared to a current price of €0.25 — trading 3.3% above its estimated fair value. The current ROE % Adjusted to Book Value is -20.68%. Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's overall GF Score™ is 72/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co (FRA:FDY), the current ROE % Adjusted to Book Value is -20.68% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co (FRA:FDY) Overvalued in 2026?
Based on GuruFocus' analysis, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co stock appears to be overvalued.
The current stock price of €0.25 is trading 3.3% above its estimated GF Value™ of €0.24.
Key valuation signals for FRA:FDY:
ROE % Adjusted to Book Value: -20.68%
GF Value™: €0.24 vs. price of €0.25 (3.3% above fair value)
No single metric tells the full story. See the FRA:FDY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Business Description
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd is engaged in the research, development, manufacturing, and sale of biopharmaceutical products. Its product portfolio includes ALA (Aminolevulinic acid Hydrochloride); FuMeiDa and Libord. The company has launched it's four types of photodynamic drugs in China market, namely hematoporphyrin, aminolevulinic acid hydrochloride, Verteporfin and Hemoporfin. Geographically, it derives revenue from Mainland China.
72GF Score
Get the complete analysis for FRA:FDY
ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:FDY has been successfully added to your 
